Second-line treatment for malignant pleural mesothelioma

Cancer Treatment Reviews

Volumn 36, Issue 1, 2010, Pages 24-32

  Ceresoli, Giovanni Luca ^a,b   Zucali, Paolo Andrea ^b   Gianoncelli, Letizia ^b   Lorenzi, Elena ^b   Santoro, Armando ^b  

^a Humanitas Gavazzeni Hospital   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Chemotherapy; Mesothelioma; Second line therapy; Targeted therapy

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTINEOPLASTIC AGENT; BELINOSTAT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IRINOTECAN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PEMETREXED; PLACEBO; RALTITREXED; RANPIRNASE; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TUMOR HOMING PEPTIDE HUMAN TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VORINOSTAT;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHILL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LOW DRUG DOSE; LUNG INFILTRATE; MALIGNANT MESOTHELIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 74649084445     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.09.003     Document Type: Review

References (96)

1. Robinson B.W.S., and Lake R.A. Advances in malignant mesothelioma. N Engl J Med 353 (2005) 1591-1603
2. Ceresoli G.L., Gridelli C., and Santoro A. Multisciplinary treatment of malignant pleural mesothelioma. Oncologist 12 (2007) 850-863
3. Scagliotti G.V., Shin D.M., Kindler H.L., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
4. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
5. Hazarika M., White R.M., Booth B.P., et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11 (2005) 982-992
6. Ceresoli G.L., Zucali P.A., Favaretto A.G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 (2006) 1443-1448
7. Castagneto B., Botta M., Aitini E., et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19 (2008) 370-373
8. Santoro A., O'Brien M.E., Stahel R.A., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 3 (2008) 756-763
9. Fennell D.A., Gaudino G., O'Byrne K.J., Mutti L., and Van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5 (2008) 136-147
10. Harvey V.J., Slevin M.L., Ponder B.A., Blackshaw A.J., and Wrigley P.F. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 54 (1984) 961-964
11. Hoffman KR. Paclitaxel and carboplatin combination chemotherapy is an effective palliative treatment for malignant mesothelioma. Proc Am Soc Clin Oncol 1996;abstr. 1428.
12. Vogelzang N.J. Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?. J Clin Oncol 17 (1999) 2626-2627
13. Karthaus M, Frieler F, Plahl A, Wert N, Tagizadeh K, Metzner D. Second line chemotherapy for patients with malignant mesothelioma (MPM) pretreated with pemetrexed and platinum. In: 2005 ASCO annual meeting proceedings, J Clin Oncol 2005;23(16S, Part I of II (June 1 Supplement)):7331.
14. Giaccone G., O'Brien M.E.R., Byrne M.J., et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 38 Suppl. 8 (2002) 19-24
15. Porta C., Zimatore M., Bonomi L., et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48 (2005) 429-434
16. Fizazi K., Doubre H., Le Chevalier T., et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21 (2003) 349-354
17. Fennell D.A., Steele J.P., Shamash J., et al. Efficacy and safety of first- or second-line irinotecan, cisplatin and mitomycin in mesothelioma. Cancer 109 (2007) 93-99
18. Curran D., Sahmoud T., Therasse P., et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16 (1998) 145-152
19. Steele J.P., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., and Rudd R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18 (2000) 3912-3917
20. Stebbing J., Powles T., McPherson K., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63 (2009) 94-97
21. Sørensen J.B., Sundstrom S., Perell K., and Thielsen A.K. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2 (2007) 147-152
22. Jänne P.A., Wozniak A.J., Bellini C.P., et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 1 (2006) 506-512
23. Taylor P., Castagneto B., Dark G., et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an international expanded access program. J Thorac Oncol 3 (2008) 761-764
24. Jassem J., Ramlau R., Santoro A., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26 (2008) 1698-1704
25. Manegold C., Symanowski J., Gatzemeier U., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16 (2005) 923-927
26. Razak A.R., Chatten K.J., and Hughes A.N. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer 60 (2008) 294-297
27. Serke M, Bauer T. Pemetrexed in second-line therapy in patients with malignant pleural mesotelioma. In: 2007 ASCO annual meeting proceedings Part I, J Clin Oncol 2007;25(18S (June 20 Supplement):18198.
28. De Vincenzo F, Zucali PA, Ceresoli GL, et al. Re-treatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma (MPM): an observational study. In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 163.
29. Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schonfeld N, Serke M. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 2008;18:3(1):34 [Epub ahead of print].
30. Zucali P.A., Ceresoli G.L., Garassino I., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112 (2008) 1555-1561
31. Zucali P.A., and Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 42 (2006) 2706-2714
32. Ohta Y., Shridhar V., Bright R.K., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81 (1999) 54-61
33. Strizzi L., Catalano A., Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193 (2001) 468-475
34. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). In: 2007 ASCO annual meeting proceedings Part I, J Clin Oncol 2007:25(18S (June 20 Supplement)):7526.
35. Ceresoli GL, Zucali PA, De Vincenzo F, et al. Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma (MPM). In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 11.
36. Kindler HL, Vogelzang NJ, Chien K, et al. SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001:20(abstr. 1359).
37. Baas P., Boogerd W., Dalesio O., Haringhuizen A., Custers F., and Van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48 (2005) 291-296
38. Pavlakis N, Abraham R, Harvie R, et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma (MM): interim results from two parallel non randomized phase II studies. Lung Cancer 2003;41(Suppl. 2):S11, abstr. O-26. Abstract of the 10th world conference on lung cancer.
39. Dowell J.E., and Kindler H.L. Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin N Am 19 (2005) 1137-1145
40. Janne PA, Wang XF, Krug LM, Hodgson L, Vokes EE, Kindler HL. Sorafenib in malignant pleural mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). In: 2007 ASCO annual meeting proceedings Part I, J Clin Oncol 2007:25(18S (June 20 Supplement)):7707.
41. Nowak A, Millward M, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 116.
42. Byrne M.J., and Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15 (2004) 257-260
43. 18F-FDG PET scans. J Nucl Med 48 (2007) 1449-1458
44. Ceresoli G.L., Chiti A., Zucali P.A., et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with 18-F fluorodeoxyglucose. J Clin Oncol 24 (2006) 4587-4593
45. Buckstein R., Meyer R.M., Seymour L., et al. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol 14 (2007) 154-161
46. Garland LL, Chansky K, Wozniak A, et al. SWOG S0509: a phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol 2009;27:15s (Suppl; abstr. 7511).
47. Schiller J.H., Storer B.E., Witt P.L., et al. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res 51 (1991) 1651-1658
48. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., and Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18 (2000) 1185-1190
49. Curnis F., Sacchi A., and Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 110 (2002) 475-482
50. Zucali PA, Gregorc V, Ceresoli GL, et al. NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): preliminary results of a multicenter phase II trial. In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 10.
51. Edwards J.G., Cox G., Andi A., et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85 (2001) 863-868
52. Arber D., Tamayo R., and Weiss L.M. Paraffin section detection of the c-kit gene product (CD 117) in human tissue: value in the diagnosis of mast cell disorders. Hum Pathol 29 (1998) 498-504
53. Mathy A., Baas P., Dalesio O., and Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50 (2005) 83-86
54. Porta C., Mutti L., and Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 59 (2007) 149-150
55. Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003;22:228S (abstr. 912).
56. Villano JL, Husain AN, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL. A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). In: 2004 ASCO annual meeting proceedings (post-meeting edition), J Clin Oncol 2004:22(14S (July 15 Supplement)):7200.
57. Edwards J.G., Swinson D.E.B., Jones J.L., Waller D.A., and O'Byrne K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54 (2006) 399-407
58. Destro A., Ceresoli G.L., Falleni M., et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51 (2006) 207-215
59. Janne P.A., Taffaro M.L., Salgia R., and Johnson B.E. Inhibition of epidermal growth factor signalling in malignant pleural mesothelioma. Cancer Res 62 (2002) 5242-5247
60. Jackman D.M., Kindler H.L., Yeap B.Y., et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113 (2008) 808-814
61. Govindan R., Kratzke R.A., Herndon II J.E., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11 (2005) 2300-2304
62. Garland L.L., Rankin C., Gandara D.R., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25 (2007) 2406-2413
63. Cortese J.F., Gowda A.L., Wali A., Eliason J.F., Pass H.I., and Everson R.B. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118 (2006) 521-522
64. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
65. Deroanne C.F., Bonjean K., Servotte S., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21 (2002) 427-436
66. Ramalingam S.S., Belani C.P., Ruel C., et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 4 (2009) 97-101
67. Porta C., Paglino C., and Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesotelioma. Biologics 2 (2008) 601-609
68. Mikulski S.M., Costanzi J.J., Vogelzang N.J., et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20 (2002) 274-281
69. Reck M, Krzakowski M, Jassem J, et al. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). J Clin Oncol 2009;27:15s (Suppl; abstr. 7507).
70. Scagliotti G.V., and Selvaggi G. Emerging drugs for mesothelioma. Expert Opin Emerg. Drugs 12 (2007) 127-137
71. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 (2002) 4645-4655
72. Ogino H., Yano S., Kakiuchi S., et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett 265 (2008) 55-66
73. Betta PG, Castagneto B, Libener R, et al. The tyrosine kinase inhibitor ZD6474 inhibits cell proliferation and induces apoptosis in malignant mesothelioma. Ann Oncol 2006;17(Suppl. 9):ix57, abstr. 92PD.
74. www.clinicaltrials.gov; A randomized Phase II trial to evaluate the efficacy and safety of Vandetanib (ZD6474, ZACTIMA™) versus vinorelbine in patients with inoperable or relapsed malignant mesothelioma; NCT00597116.
75. Atkins M.B., Yasotan U., and Kirkpatrick P. Everolimus. Nat Rev Drug Discov 8 (2009) 535-536
76. O'Donnell A., Faivre S., Burris H.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26 (2008) 1588-1595
77. www.clinicaltrials.gov; Phase II trial of mTOR inhibitor, Everolimus (RAD001), in malignant pleural mesothelioma (MPM); NCT00770120.
78. Sartore-Bianchi A., Gasparri F., Galvani A., et al. Bortezomib inhibits nuclear factor-kB-dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13 (2007) 5942-5951
79. Gordon G.I., Mani M., Maulik G., et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61 (2008) 549-558
80. www.clinicaltrials.gov; An open label phase II multicentre clinical trial of single agent bortezomib in patients with malignant pleural mesothelioma; NCT00513877.
81. Krug L.M., Curley T., Schwartz L., et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 7 (2006) 257-261
82. www.clinicaltrials.gov; A phase III, randomized, double-blin, placebo-controlled trial of oral suberoylanilide hydroxamic acid (SAHA) in patients with advanced malignant pleural mesothelioma previously treated with systemic chemotherapy; NCT00128102.
83. Krug LM, Marangolo M, Kindler HL, et al. A phase III, randomized, double-blind, placebo-controlled trial of vorinostat in patients with (MPM) previously treated with systemic chemotherapy. In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 223.
84. Bertino P., Porta C., Barbone D., et al. Preliminary data suggestive of a novel translational approach to mesothelioma therapy: imatinib mesylate with gemcitabine or pemetrexed. Thorax 62 (2007) 690-695
85. Bertino P., Piccardi F., Porta C., et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 14 (2008) 541-548
86. Ali Y., Lin Y., Gharibo M.M., et al. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res 13 (2007) 5876-5882
87. www.clinicaltrials.gov; A Phase II study of the association of Glivec® plus Gemzar® in patients with unresectable, refractory, malignant mesothelioma; NCT00551252.
88. Tsao A.S., He D., Saigal B., et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6 (2007) 1962-1972
89. www.clinicaltrials.gov; A phase II study of Dasatinib (NSC #732517) in patients with previously treated malignant mesothelioma; NCT00509041.
90. Hassan R., and Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 44 (2008) 46-53
91. Malumbres M., and Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1 (2001) 222-231
92. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatments. J Clin Oncol 24 (2006) 1770-1783
93. Lopez-Rios F., Chuai S., Flores S., et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66 (2006) 2970-2979
94. Jagadeeswaran R., Ma P.C., Seiwert T.Y., et al. Functional analysis of c-Met/Hepatocyte Growth Factor pathway in malignant pleural mesothelioma. Cancer Res 66 (2006) 352-361
95. Pollak M. Insuline and insuline-like growth factors signalling in neoplasia. Nat Rev Cancer 8 (2008) 915-928
96. Whitson B.A., Jacobson B.A., Frizelle S., et al. Effects of insuline-like growth factor-1 receptor inhibition in mesothelioma. Ann Thorac Surg 82 (2006) 996-1002